Results 191 to 200 of about 747,119 (356)

Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population. [PDF]

Genes (Basel), 2022
Zhang F, Mu G, Liu Z, Xie Q, Zhang H, Zhou S, Wang Z, Hu K, Wang Z, Zhao X, Cui Y, Xiang Q.   +11 more
europepmc   +1 more source

Activated Partial Thromboplastin Time Abnormality in Patients with Cholangiocarcinoma [PDF]

, 2004
Viroj Wiwanitkit
openalex   +1 more source

Activated Protein C Resistance Testing: An Update From Australasia/Asia‐Pacific

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Activated protein C resistance (APCR) represents a risk factor for thrombosis and is usually due to factor V Leiden (FVL). Clinicians may order either test (i.e., APCR or FVL) to help assess ‘thrombophilia’ in patients who present with thrombosis. APCR testing is usually achieved using clot‐based assays, whereas FVL is assessed by
Emmanuel J. Favaloro, Sandya Arunachalam, Elysse Dean, Mahzuza Salwa, Monica Ahuja, Lynne Connelly, Kent Chapman, Ronny Vong, Leonardo Pasalic   +8 more
wiley   +1 more source

Changes in Some Haemostatic Parameters Among Patients with Chronic Kidney Disease in Kano Metropolis

Sokoto Journal of Medical Laboratory Science, 2017
It has long been accepted that Chronic Kidney Disease (CKD) causes alterations in haemostatic parameters.  These changes have not been reported in our community.
Usman, M. D., *Garba, N., Danladi, S.B., Isah, S.Y., Audu, A., Dakata A.M., and Jelani, I.
doaj  

Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis. [PDF]

Yonago Acta Med, 2022
Kato K, Hatayama Y, Shimohiro H, Ichikawa H, Fukuda T.   +4 more
europepmc   +1 more source

Comparing a piezoelectric quartz crystal with an optical coagulometer in monitoring high-dose heparin therapy by determining whole blood activated partial thromboplastin time and activated clotting time [PDF]

, 2005
Tsun‐Mei Lin, Tzong‐Jih Cheng, Tsui-Hsun Wu, Hsien‐Chang Chang   +3 more
openalex   +1 more source

Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani, Chee Wee Tan, Deborah M. Siegal   +2 more
wiley   +1 more source

From Activated Partial Thromboplastin Time to Antifactor Xa and Back Again. [PDF]

Am J Clin Pathol, 2022
May JE, Siniard RC, Taylor LJ, Marques MB, Gangaraju R.   +4 more
europepmc   +1 more source

Activated Partial Thromboplastin Time as a Screening Test of Minor or Moderate Coagulation Factor Deficiencies for Canine Plasma: Sensitivity of Different Commercial Reagents

, 2000
Reinhard Mischke
openalex   +1 more source

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source